• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Saudi Arabia·Healthcare·4018.SR
Share

Almoosa Health Company Stocks

SAR 99.8Last Updated 26.10.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

SAR 1.22B

SAR 99.8
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Almoosa Health Company functions as a private healthcare provider situated in Saudi Arabia. The firm engages in storing medical goods and distributing pharmaceuticals, beauty products, and single-use medical supplies. Additionally, it oversees the operation of hospitals and pharmacies, offering a comprehensive suite of services that includes critical care, active rehabilitation, extended care, in-home healthcare assistance, and health-related educational programs. Founded in 1996, the company is headquartered in Al Mubarraz, Saudi Arabia, and operates as a subsidiary of Abdulaziz bin Abdullah Almoosa Investment Company.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 4018.SR is 132 and suggests 32% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.10.2026 03:18

"The conditions for a rebound are ripe": Stocks rise for a second day ahead of big tech earnings reports

28.10.2026 03:13

Oracle is expanding its partnership with OpenAI and integrating Google chips into its infrastructure

28.10.2026 00:20

Memory stocks cool off in 2H26 amid AI spending doubts

27.10.2026 22:38

GM will move its listing to the Nasdaq. What does this mean for its stock?

27.10.2026 21:09

Boeing shares plunge as 737 Max ramp-up delays overshadow top-line growth in 3Q

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026